Treatment of liver disease depends on an accurate diagnosis and prediction about the risk for progression. The current diagnostic gold standard is a needle biopsy, an invasive procedure with associated risks. We urgently need non-invasive substitutes to advance our mechanistic understanding of liver diseases, determine disease states, and monitor patients. The high-risk, high-gain project seeks to transfer the breakthrough development for genome-wide assaying of cell-free nucleosomes, termed cfChlP-seq, to Berlin, jointly develop it further (by aligning circulating cfChlp-seq with tissue single-cell data) and explore its clinical utility in two areas of high-unmet medical need.
Funding period: 10/2022 - 10/2025
Contact:
Prof. Dr. Frank Tacke
Charité - Universitätsmedizin Berlin
Augustenburger Platz 1
13353 Berlin
Phone: +49 30 450 653021
Applicant: Humboldt-Universität zu Berlin
Partner: Hebrew University Jerusalem, Max-Dellbrück-Center for Molecular Medicine
